Multaq
FDA to Review Multaq After Sanofi Halts Clinical Trial
The FDA has decided to review the atrial fibrillation medication Multaq after the makers of the medication stopped a clinical trial when some of the patients developed cardiovascular problems. The...
Multaq
Heart Drug Multaq has Higher Death Rate, FDA warns
GregJonesLaw_3Q42_2011-08-25_Thu_Heart Drug Multaq has Higher Death Rate, FDA Warns Federal health regulators have been warning doctors that a heart drug made by Sanofi has been associated with fatal heart problems....
Multaq
Health Canada Advising Doctors Against Prescribing Multaq
After recent research studies have discovered that Multaq can increase a patient’s chance of suffering from severe cardiovascular complications, Health Canada is advising doctors not to prescribe the drug Multaq...